CoChat
Sign Up
Cited by 192Neuroinflammation and Neurodegeneration MechanismsAlzheimer's disease research and treatmentsNeurological Disease Mechanisms and Treatments

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

Blocking microglial activation of reactive astrocytes is neuroprotective in models of Alzheimer’s disease

Open access
Park, Jong-Sung, Kam, Tae-In, Lee, Saebom, Park, Hyejin, Oh, Yumin, Kwon, Seung-Hwan, Song, Jae-Jin, Kim, Donghoon, Kim, Hyunhee, Jhaldiyal, Aanishaa, Na, Dong Hee, Lee, Kang Choon, Park, Eun Ji, Pomper, Martin G., Pletnikova, Olga, Troncoso, Juan C., Ko, Han Seok, Dawson, Valina L., Dawson, Ted M., Lee, Seulki·2021·Acta Neuropathologica Communications
DOI 10.1186/s40478-021-01180-zPMC PMC8074239
Open this paper in CoChat — free accountOpen PDF

Abstract

Alzheimer’s disease (AD) is the most common cause of age-related dementia. Increasing evidence suggests that neuroinflammation mediated by microglia and astrocytes contributes to disease progression and severity in AD and other neurodegenerative disorders. During AD progression, resident microglia undergo proinflammatory activation, resulting in an increased capacity to convert resting astrocytes to reactive astrocytes. Therefore, microglia are a major therapeutic target for AD and blocking microglia-astrocyte activation could limit neurodegeneration in AD. Here we report that NLY01, an engineered exedin-4, glucagon-like peptide-1 receptor (GLP-1R) agonist, selectively blocks β-amyloid (Aβ)-induced activation of microglia through GLP-1R activation and inhibits the formation of reactive astrocytes as well as preserves neurons in AD models. In two transgenic AD mouse models (5xFAD and 3xTg-AD), repeated subcutaneous administration of NLY01 blocked microglia-mediated reactive astrocyte conversion and preserved neuronal viability, resulting in improved spatial learning and memory. Our study indicates that the GLP-1 pathway plays a critical role in microglia-reactive astrocyte associated neuroinflammation in AD and the effects of NLY01 are primarily mediated through a direct action on Aβ-induced GLP-1R+ microglia, contributing to the inhibition of astrocyte reactivity. These results show that targeting upregulated GLP-1R in microglia is a viable therapy for AD and other neurodegenerative disorders.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40478-021-01180-z

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 NLY01 ameliorates behavioral deficits in 5xFAD mice. 3-month-old 5xFAD mice were treated with PBS or NLY01 (1 or 10 mg/kg) subcutaneously (s.c.) for 4 months (n = 9–13 per group). a Mice were trained and tested on the spatial memory version of the Morris water maze (MWM; indicated by solid lines at 60 s escape latency) (n = 9–13 per group). b Representative swimming traces for training trials on day 5 are shown. c Mice were given a memory probe with the platform removed at 24 h after the last training trial (n = 9–13 per group). d Representative swimming traces of the memory test at 24 h after the last training trial. e Swimming speed of WT mice and 5xFAD mice treated with vehicle or NLY01 (1 or 10 mg/kg) (n = 9–13 per group). f Mice were tested on a spatial alternation task in a Y-maze (n = 11–13 per group). Data are shown as the mean ± SEM. p values were determined by one-way ANOVA. #p < 0.05, ###p < 0.001 versus WT + PBS; *p < 0.05 versus 5xFAD + PBS
Fig. 1 NLY01 ameliorates behavioral deficits in 5xFAD mice. 3-month-old 5xFAD mice were treated with PBS or NLY01 (1 or 10 mg/kg) subcutaneously (s.c.) for 4 months (n = 9–13 per group). a Mice were trained and tested on the spatial memory version of the Morris water maze (MWM; indicated by solid lines at 60 s escape latency) (n = 9–13 per group). b Representative swimming traces for training trials on day 5 are shown. c Mice were given a memory probe with the platform removed at 24 h after the last training trial (n = 9–13 per group). d Representative swimming traces of the memory test at 24 h after the last training trial. e Swimming speed of WT mice and 5xFAD mice treated with vehicle or NLY01 (1 or 10 mg/kg) (n = 9–13 per group). f Mice were tested on a spatial alternation task in a Y-maze (n = 11–13 per group). Data are shown as the mean ± SEM. p values were determined by one-way ANOVA. #p < 0.05, ###p < 0.001 versus WT + PBS; *p < 0.05 versus 5xFAD + PBSCC BY · PubMed Central
Fig. 2 GLP-1R is increased in the hippocampus of AD brains and in microglia exposed to Aβ1-42. a, b Relative GLP-1R mRNA expression in the hippocampus from the brain of a AD patients (n = 6 per group) and b 5xFAD mice (7-month-old; n = 7 per group). c Representative confocal images with GLP-1R (red) and DAPI (blue) in the hippocampus of 5xFAD mice (scale bars, 20 μm) and quantification of the GLP-1R immunostaining (n = 4 per group). d Representative confocal images of immunostaining with GLP-1R (red), MAP2 (green; upper), GFAP (green; middle), Iba-1 (green; lower), and DAPI (blue) in the hippocampus from 3xTg-AD mice (12-month-old; n = 3) (scale bar, 50 μm). e Primary astrocytes, microglia, and neurons were incubated with oligomeric Aβ1-42 (1 μM) for 4 h. The levels of GLP-1R (exposed to a short or long time), GFAP, Iba-1, Tuj1, and β-actin were determined using Western blot. Quantification of GLP-1R is shown as relative protein expression normalized to β-actin (n = 3 biologically independent cell cultures). Data are shown as the mean ± SEM. p values were determined by two-tailed unpaired t-test or one-way ANOVA. #p < 0.05, ##p < 0.01 versus WT or astrocyte + PBS; **p < 0.01 versus microglia + PBS
Fig. 2 GLP-1R is increased in the hippocampus of AD brains and in microglia exposed to Aβ1-42. a, b Relative GLP-1R mRNA expression in the hippocampus from the brain of a AD patients (n = 6 per group) and b 5xFAD mice (7-month-old; n = 7 per group). c Representative confocal images with GLP-1R (red) and DAPI (blue) in the hippocampus of 5xFAD mice (scale bars, 20 μm) and quantification of the GLP-1R immunostaining (n = 4 per group). d Representative confocal images of immunostaining with GLP-1R (red), MAP2 (green; upper), GFAP (green; middle), Iba-1 (green; lower), and DAPI (blue) in the hippocampus from 3xTg-AD mice (12-month-old; n = 3) (scale bar, 50 μm). e Primary astrocytes, microglia, and neurons were incubated with oligomeric Aβ1-42 (1 μM) for 4 h. The levels of GLP-1R (exposed to a short or long time), GFAP, Iba-1, Tuj1, and β-actin were determined using Western blot. Quantification of GLP-1R is shown as relative protein expression normalized to β-actin (n = 3 biologically independent cell cultures). Data are shown as the mean ± SEM. p values were determined by two-tailed unpaired t-test or one-way ANOVA. #p < 0.05, ##p < 0.01 versus WT or astrocyte + PBS; **p < 0.01 versus microglia + PBSCC BY · PubMed Central
Fig. 3 NLY01 suppresses Aβ-induced microglia activation. a Primary microglia were pre-treated with PBS or NLY01 (1 μM) for 30 min, and then further incubated with oligomeric Aβ1-42 (1 μM) for 4 h. mRNA levels of TNF-α, C1q, IL-1α, IL-1β, and IL-6 were determined using qPCR (n = 3 biologically independent cell cultures). b Cytokine release in media from primary microglia incubated with oligomeric Aβ1-42 (1 μM) for 18 h. TNF-α, C1q, IL-1α, and IL-1β were measured by ELISA (n = 4 biologically independent cell cultures). c GLP-1R and β-actin expression in lenti-CRISPR/Cas9 mediated GLP-1R KO microglia. Quantification of GLP-1R shown as relative protein expression normalized to β-actin (n = 3 biologically independent cell cultures). d mRNA levels of TNF-α, C1q, IL-1α, IL-1β, and IL-6 in oligomeric Aβ1-42 (1 μM) treated lenti-CRISPR/Cas9 mediated GLP-1R KO microglia (n = 4 biologically independent cell cultures). e Levels of TNF-α, C1q, IL-1α, and IL-6 analyzed by qPCR in the hippocampus of 5xFAD mice treated with PBS or NLY01 (n = 5–8 per group). Data are shown as the mean ± SEM. p values were determined by two-tailed unpaired t-test or one-way ANOVA. #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 versus Control + PBS or WT + PBS; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus Aβ1-42 + PBS or 5xFAD + PBS
Fig. 3 NLY01 suppresses Aβ-induced microglia activation. a Primary microglia were pre-treated with PBS or NLY01 (1 μM) for 30 min, and then further incubated with oligomeric Aβ1-42 (1 μM) for 4 h. mRNA levels of TNF-α, C1q, IL-1α, IL-1β, and IL-6 were determined using qPCR (n = 3 biologically independent cell cultures). b Cytokine release in media from primary microglia incubated with oligomeric Aβ1-42 (1 μM) for 18 h. TNF-α, C1q, IL-1α, and IL-1β were measured by ELISA (n = 4 biologically independent cell cultures). c GLP-1R and β-actin expression in lenti-CRISPR/Cas9 mediated GLP-1R KO microglia. Quantification of GLP-1R shown as relative protein expression normalized to β-actin (n = 3 biologically independent cell cultures). d mRNA levels of TNF-α, C1q, IL-1α, IL-1β, and IL-6 in oligomeric Aβ1-42 (1 μM) treated lenti-CRISPR/Cas9 mediated GLP-1R KO microglia (n = 4 biologically independent cell cultures). e Levels of TNF-α, C1q, IL-1α, and IL-6 analyzed by qPCR in the hippocampus of 5xFAD mice treated with PBS or NLY01 (n = 5–8 per group). Data are shown as the mean ± SEM. p values were determined by two-tailed unpaired t-test or one-way ANOVA. #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 versus Control + PBS or WT + PBS; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus Aβ1-42 + PBS or 5xFAD + PBSCC BY · PubMed Central
Fig. 4 Inhibition of Aβ-induced reactive astrocytes by NLY01. a Schematic diagram showing the treatment of astrocytes with MCM from Aβ1-42 treated microglia with or without NLY01. mRNA levels of primary astrocytes 24 h post treatment with MCM from oligomeric Aβ1-42 (1 μM)-activated microglia with or without NLY01 (1 μM) is shown (n = 3 biologically independent cell cultures). b Levels of GFAP, C3, and β-actin in the hippocampus of WT and 5 × FAD mice treated with PBS or NLY01 using Western blot. c Relative GFAP and C3 protein levels were normalized versus β-actin levels (n = 4 per group). d mRNA levels of astrocyte signatures in the isolated astrocytes from the hippocampus of WT and 5 × FAD mice treated with PBS or NLY01 using qPCR. GAPDH was used to normalize for the amounts of cDNA (n = 4 per group). Data are shown as the mean ± SEM. p values were determined by one-way ANOVA. #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 versus Control MCM or WT + PBS; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus Aβ1-42 MCM or 5xFAD + PBS
Fig. 4 Inhibition of Aβ-induced reactive astrocytes by NLY01. a Schematic diagram showing the treatment of astrocytes with MCM from Aβ1-42 treated microglia with or without NLY01. mRNA levels of primary astrocytes 24 h post treatment with MCM from oligomeric Aβ1-42 (1 μM)-activated microglia with or without NLY01 (1 μM) is shown (n = 3 biologically independent cell cultures). b Levels of GFAP, C3, and β-actin in the hippocampus of WT and 5 × FAD mice treated with PBS or NLY01 using Western blot. c Relative GFAP and C3 protein levels were normalized versus β-actin levels (n = 4 per group). d mRNA levels of astrocyte signatures in the isolated astrocytes from the hippocampus of WT and 5 × FAD mice treated with PBS or NLY01 using qPCR. GAPDH was used to normalize for the amounts of cDNA (n = 4 per group). Data are shown as the mean ± SEM. p values were determined by one-way ANOVA. #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 versus Control MCM or WT + PBS; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus Aβ1-42 MCM or 5xFAD + PBSCC BY · PubMed Central
Fig.5 Effects of NLY01 on neuronal cell death caused by Aβ1-42-induced DAA. a Schematic diagram showing treatment of neurons with Aβ1-42-astrocyte conditioned media (ACM) or directly with Aβ1-42. b Representative images showing the death of mouse primary cortical neurons (left; Propidium iodide stain in red indicates the dead cells) and quantification of cell death caused by Aβ1-42-ACM (15 μg/ml) with or without NLY01 (1 μM) (n = 6, 2 technical repeats from 3 biologically independent cell cultures). c Quantification of cell death caused by Aβ1-42-ACM (50 μg/mL) with or without NLY01 (1 μM) in human cortical neurons (n = 8, 2 technical repeats from 4 biologically independent cell cultures). d Quantification of cell death caused by Aβ1-42 treatment (5 μM) with or without NLY01 (1 μM) in human cortical neurons (n = 6). e Protein expression of MAP2, BDNF, Bcl-2, and β-actin in the hippocampus of WT and 5xFAD mice treated with PBS or NLY01. f MAP2, BDNF and Bcl-2 protein levels were normalized versus β-actin levels (n = 4 per group). g, h Aβ plaques were stained using 4G8 antibody in WT or 5xFAD mice with NLY01 treatment. g Representative images of immunostaining with 4G8 (scale bar, 200 μm) and h quantification of Aβ plaque number and Aβ load (n = 4 per group). Data are shown as the mean ± SEM. p values were determined by one-way ANOVA. #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 versus Control or WT + PBS; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.001 versus Aβ-ACM, Aβ, or 5xFAD + PBS
Fig.5 Effects of NLY01 on neuronal cell death caused by Aβ1-42-induced DAA. a Schematic diagram showing treatment of neurons with Aβ1-42-astrocyte conditioned media (ACM) or directly with Aβ1-42. b Representative images showing the death of mouse primary cortical neurons (left; Propidium iodide stain in red indicates the dead cells) and quantification of cell death caused by Aβ1-42-ACM (15 μg/ml) with or without NLY01 (1 μM) (n = 6, 2 technical repeats from 3 biologically independent cell cultures). c Quantification of cell death caused by Aβ1-42-ACM (50 μg/mL) with or without NLY01 (1 μM) in human cortical neurons (n = 8, 2 technical repeats from 4 biologically independent cell cultures). d Quantification of cell death caused by Aβ1-42 treatment (5 μM) with or without NLY01 (1 μM) in human cortical neurons (n = 6). e Protein expression of MAP2, BDNF, Bcl-2, and β-actin in the hippocampus of WT and 5xFAD mice treated with PBS or NLY01. f MAP2, BDNF and Bcl-2 protein levels were normalized versus β-actin levels (n = 4 per group). g, h Aβ plaques were stained using 4G8 antibody in WT or 5xFAD mice with NLY01 treatment. g Representative images of immunostaining with 4G8 (scale bar, 200 μm) and h quantification of Aβ plaque number and Aβ load (n = 4 per group). Data are shown as the mean ± SEM. p values were determined by one-way ANOVA. #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 versus Control or WT + PBS; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.001 versus Aβ-ACM, Aβ, or 5xFAD + PBSCC BY · PubMed Central
Fig. 6 Effects of NLY01 on 3 × Tg-AD mice. 7-month-old 3 × Tg-AD mice treated with PBS or NLY01 (1 or 10 mg/kg) subcutaneously (s.c.) for 5 months (n = 6–8 per group). a Mice were trained and tested on the spatial memory version of the Morris water maze (MWM; indicated by solid lines at 60 s escape latency) (n = 6–8 per group). b Mice were given a memory probe with the platform removed at 24 h after the last training trial. 3 × Tg-AD mice treated with NLY01 exhibited dose-dependently increased time in the target quadrant (n = 6–8 per group). c Mice were placed in a light compartment and received a mild foot shock upon crossing over to the dark compartment. Mice were tested for retention of memory at 24 h after training (n = 6–8 per group). d Mice were tested on a spatial alternation task in a Y-maze (n = 6–8 per group). e The levels of TNF-α, C1q, IL-1β, IFN-γ, and IL-6 were analyzed by qPCR in the hippocampus of mice treated with PBS or NLY01 (n = 3–5 per group). f Protein expression of GFAP and C3 in the hippocampus from WT and 3xTg-AD mice treated with PBS or NLY01 using Western blot. g GFAP and C3 protein levels were normalized versus GAPDH levels (n = 4 per group). h Representative images of western blot with MAP2, BDNF, and Bcl-2. i Protein levels of (h) were normalized versus β-actin levels (n = 4 per group). Data are shown as the mean ± SEM. p values were determined by one-way ANOVA. #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 versus WT + PBS; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus 3xTg-AD + PBS
Fig. 6 Effects of NLY01 on 3 × Tg-AD mice. 7-month-old 3 × Tg-AD mice treated with PBS or NLY01 (1 or 10 mg/kg) subcutaneously (s.c.) for 5 months (n = 6–8 per group). a Mice were trained and tested on the spatial memory version of the Morris water maze (MWM; indicated by solid lines at 60 s escape latency) (n = 6–8 per group). b Mice were given a memory probe with the platform removed at 24 h after the last training trial. 3 × Tg-AD mice treated with NLY01 exhibited dose-dependently increased time in the target quadrant (n = 6–8 per group). c Mice were placed in a light compartment and received a mild foot shock upon crossing over to the dark compartment. Mice were tested for retention of memory at 24 h after training (n = 6–8 per group). d Mice were tested on a spatial alternation task in a Y-maze (n = 6–8 per group). e The levels of TNF-α, C1q, IL-1β, IFN-γ, and IL-6 were analyzed by qPCR in the hippocampus of mice treated with PBS or NLY01 (n = 3–5 per group). f Protein expression of GFAP and C3 in the hippocampus from WT and 3xTg-AD mice treated with PBS or NLY01 using Western blot. g GFAP and C3 protein levels were normalized versus GAPDH levels (n = 4 per group). h Representative images of western blot with MAP2, BDNF, and Bcl-2. i Protein levels of (h) were normalized versus β-actin levels (n = 4 per group). Data are shown as the mean ± SEM. p values were determined by one-way ANOVA. #p < 0.05, ##p < 0.01, ###p < 0.001, ####p < 0.0001 versus WT + PBS; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus 3xTg-AD + PBSCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

Sorted by citations

See all 192

Related

See all

Metadata

Authors
Park, J.-S., Kam, T.-I., Lee, S., Park, H., Oh, Y., Kwon, S.-H., Song, J.-J., Kim, D., Kim, H., Jhaldiyal, A., Na, D. H., Lee, K. C., Park, E. J., Pomper, M. G., Pletnikova, O., Troncoso, J. C., Ko, H. S., Dawson, V. L., Dawson, T. M., & Lee, S.
Affiliations
  • Johns Hopkins University (US)
  • Chung-Ang University (KR)
Corresponding author
  • Lee, Saebom
  • Lee, Seulki
ORCID
Venue
Acta Neuropathologica Communications
Publisher
Springer Science and Business Media LLC
Published
2021-04-26
Volume
9
Issue
1
Pages
78-78
ISSN
2051-5960 (ISSN-L)
DOI
10.1186/s40478-021-01180-z
PMC
PMC8074239
OpenAlex
W3157204291
Cited by
192
References
41
Citations by year
2026: 30 · 2025: 43 · 2024: 44 · 2023: 41 · 2022: 23 · 2021: 11
FWCI
11.87
Type
journal article
Language
en
Open access
Licence
Locations
  • Acta Neuropathologica Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Edward N. and Della L. Thome Memorial Foundation
  • Maryland Stem Cell Research Fund (2018-MSCRFD-4338)
  • National Institute of Neurological Disorders and Stroke (NS38377, NS107404)
  • JPB Foundation
  • National Research Foundation of Korea
Topics
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
Keywords
Alzheimer's disease, microglial activation, reactive astrocytes, neuroinflammation, GLP-1 receptor agonists, exenatide, amyloid-beta, astrocyte-microglia interaction, neuroprotection, 5xFAD mice, 3xTg-AD mice, spatial learning and memory, neurodegeneration
MeSH terms
Neuroprotection, Glucagon-Like Peptide-1 Receptor, Exenatide, Glucagon-Like Peptide-1 Receptor Agonists, Alzheimer Disease, Animals, Astrocytes, Cells, Cultured, Humans, Male, Mice, Transgenic, Peptide Fragments, Amyloid beta-Peptides, Microglia, Neuroprotective Agents, Maze Learning, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review